NON-MEDICAL SWITCH BETWEEN ADALIMUMAB BIOSIMILARS AND FROM THE ORIGINATOR ADALIMUMAB TO BIOSIMILARS IN INFLAMMATORY BOWEL DISEASE PATIENTS - A MULTICENTRE STUDY ON EFFICACY AND DRUG SUSTAINABILITY

被引：0
|
作者：
Lontai, Livia
Gonczi, Lorant
Balogh, Fruzsina
Komlodi, Nora
Resal, Tamas
Farkas, Klaudia
Molnar, Tamas
Miheller, Pal
Golovics, Petra A.
Schafer, Eszter
Szamosi, Tamas
Ilias, Akos
Lakatos, Peter L.
机构：
来源：
GASTROENTEROLOGY | 2022年 / 162卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Su1507
引用
收藏
页码：S606 / S606
页数：1
相关论文
共 50 条
  • [21] Safety and clinical efficacy of double switch from originator infliximab to biosimilars CT-P13 and SB2 in patients with inflammatory bowel diseases (SCESICS): A multicentre study
    Mazza, S.
    Fasci, A.
    Casini, V.
    Ricci, C.
    Munari, F.
    Pirola, L.
    Girelli, C.
    Lupinacci, G.
    Pastorelli, L.
    Cavallaro, F.
    O'Sed, N. Piazza
    Ferraris, L.
    Colucci, A.
    Amato, A.
    Maurizio, V.
    Fiorino, G.
    Caprioli, F.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S342 - S342
  • [22] Analysis of the effectiveness and safety of switching from originator to biosimilar adalimumab in patients with Inflammatory Bowel Disease
    Casanova, M. J.
    Chaparro, M.
    Nantes, O.
    Varela, P.
    Vela-Gonzalez, M.
    Montserrat, R.
    Sierra, O. G.
    Riestra, S.
    Barreiro-de Acosta, M.
    Martin-Rodriguez, M. M.
    Gargallo-Puyuelo, C. J.
    Reygosa, C.
    Munoz, R.
    Garcia de la Filia-Molina, I.
    Nunez-Ortiz, A.
    Kolle, L.
    Calafat, M.
    Huguet, J. M.
    Iglesias-Flores, E.
    Martinez-Perez, T. J.
    Bosch, O.
    Duque-Alcorta, J. M.
    Frago-Larramona, S.
    Sanchez-Azofra, M.
    Van Domselaar, M.
    Gonzalez-Cosano, V. M.
    Bujanda, L.
    Rubio, S.
    Mancebo, A.
    Castro, B.
    Garcia-Lopez, S.
    de Francisco, R.
    Nieto, L.
    Laredo, V.
    Gutierrez, A.
    Mesonero, F.
    Leo-Carnerero, E.
    Canete, F.
    Ruiz, L.
    Gisbert, J. P.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I474 - I475
  • [23] Analysis of the effectiveness and safety of switching from originator to biosimilar adalimumab in patients with Inflammatory Bowel Disease
    Casanova, M. J.
    Chaparro, M.
    Nantes, O.
    Varela, P.
    Vela-Gonzalez, M.
    Montserrat, R.
    Sierra, O. G.
    Riestra, S.
    Barreiro-de Acosta, M.
    Martin-Rodriguez, M. M.
    Gargallo-Puyuelo, C. J.
    Reygosa, C.
    Munoz, R.
    Garcia de la Filia-Molina, I.
    Nunez-Ortiz, A.
    Kolle, L.
    Calafat, M.
    Huguet, J. M.
    Iglesias-Flores, E.
    Martinez-Perez, T. J.
    Bosch, O.
    Duque-Alcorta, J. M.
    Frago-Larramona, S.
    Sanchez-Azofra, M.
    Van Domselaar, M.
    Gonzalez-Cosano, V. M.
    Bujanda, L.
    Rubio, S.
    Mancebo, A.
    Castro, B.
    Garcia-Lopez, S.
    de Francisco, R.
    Nieto, L.
    Laredo, V.
    Gutierrez, A.
    Mesonero, F.
    Leo-Carnerero, E.
    Canete, F.
    Ruiz, L.
    Gisbert, J. P.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I474 - I475
  • [24] SAFETY AND CLINICAL EFFICACY OF DOUBLE SWITCH FROM ORIGINATOR INFLIXIMAB TO BIOSIMILARS CT-P13 AND SB2 IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES (SCESICS): A MULTICENTRE STUDY.
    Mazza, Stefano
    Fasci', Alberto
    Casini, Valentina
    Ricci, Chiara
    Munari, Francesca
    Pirola, Lorena
    Girelli, Carlo M.
    Lupinacci, Guido
    Pastorelli, Luca
    Cavallaro, Flaminia
    O'Sed, Nicole Piazza
    Ferraris, Luca
    Colucci, Alice
    Amato, Arnaldo
    Vecchi, Maurizio
    Fiorino, Gionata
    Caprioli, Flavio
    GASTROENTEROLOGY, 2020, 158 (06) : S957 - S957
  • [25] EFFECTIVENESS AND SAFETY OF NON-MEDICAL SWITCH FROM RITUXIMAB ORIGINATOR TO AND AMONG BIOSIMILARS IN SMALL VESSEL VASCULITIDES PATIENTS: REAL WORLD DATA FROM A RETROSPECTIVE MONOCENTRIC STUDY
    Stano, S.
    Coladonato, L.
    Capuano, A.
    Lavista, M.
    Spedicato, V.
    Fornaro, M.
    Iannone, F.
    Cacciapaglia, F.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1596 - 1597
  • [26] Are Comorbidities in Patients with Chronic Inflammatory Rheumatic Diseases Associated with Treatment Adherence to Biosimilars in a Non-medical Switch Scenario?
    Redeker, Imke
    Moustakis, Stefan
    Tsiami, Styliani
    Baraliakos, Xenofon
    Andreica, Ioana
    Buehring, Bjoern
    Braun, Juergen
    Kiltz, Uta
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 468 - 472
  • [27] THE RETENTION RATE OF ETANERCEPT AND ADALIMUMAB IN FIRST-LINE AND AFTER NON-MEDICAL SWITCH IN PATIENTS WITH PSORIATIC ARTHRITIS: A COMPARISON BETWEEN ORIGINATORS AND BIOSIMILARS. A SINGLE-CENTER RETROSPECTIVE STUDY.
    Rella, V.
    Rotondo, C.
    Maruotti, N.
    Altomare, A.
    Erroi, F.
    Stefania, S.
    Trotta, A.
    Cantatore, F. P.
    Corrado, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1794 - 1794
  • [28] THE RETENTION RATE OF ETANERCEPT AND ADALIMUMAB IN FIRST-LINE AND AFTER NON-MEDICAL SWITCH IN PATIENTS WITH PSORIATIC ARTHRITIS: A COMPARISON BETWEEN ORIGINATORS AND BIOSIMILARS. A SINGLE-CENTER RETROSPECTIVE STUDY.
    Hannech, E.
    Miladi, S.
    Fazaa, A.
    Boussaa, H.
    Yasmine, M.
    Souabni, L.
    Ouenniche, K.
    Kassab, S.
    Chekili, S.
    Ben Abdelghani, K.
    Laatar, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1794 - 1794
  • [29] Effectiveness of non-medical switch from adalimumab bio-originator to SB5 biosimilar and from ABP501 adalimumab biosimilar to SB5 biosimilar in patients with chronic inflammatory arthropathies: a monocentric observational study
    Scrivo, R.
    Castellani, C.
    Mancuso, S.
    Sciarra, G.
    Giardina, F.
    Bevignani, G.
    Ceccarelli, F.
    Spinelli, F. R.
    Alessandri, C.
    Di Franco, M.
    Riccieri, V.
    Priori, R.
    Conti, F.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2023, 41 (03) : 613 - 619
  • [30] ARE COMORBIDITIES IN PATIENTS WITH CHRONIC INFLAMMATORY RHEUMATIC DISEASES ASSOCIATED WITH TREATMENT NON-ADHERENCE TO BIOSIMILARS IN A NON-MEDICAL SWITCH SCENARIO?
    Redeker, I.
    Moustakis, S.
    Tsiami, S.
    Baraliakos, X.
    Andreica, I.
    Buehring, B.
    Braun, J.
    Kiltz, U.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1805 - 1806
12345